Rybrevant (amivantamab) plus Leclaza (lazertinib) led to promising outcomes in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) that has not previously been treated, according to findings from the CHRYSALIS-2 trial presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Findings showed that in patients who have not previously been treated, 55% responded to therapy. Additionally, the median progression-free survival (PFS), which measures how long patients live without their disease worsening, was 19.5 months.
Study author, Dr. Byoung Chul Cho, medical oncologist at the Yonsei Cancer Center in South Korea, met with CURE at the conference to discuss the CHRYSALIS-2 findings. He mentioned that although he cannot say for sure whether Rybrevant plus Leclaza has the potential to become the standard of care, the drug duo did have “very potent activity” for EGFR-mutant NSCLC.
Transcript:
Although we cannot provide a clear answer to your question with our study, we demonstrated that [Rybrevant] plus [Leclaza] has a very potent activity in a patient with atypical EGFR-mutant lung cancer. We demonstrated the longest medium PFS with this combination, and it’s almost double what we [see] with classical EGFR TKI.
In addition to PFS, we also demonstrated very promising overall survival with median follow-up of 17 months. Median survival in firstline setting was not estimable, which is fairly promising, given the fact that median overall survival with a variable EGFR TKI treatment is known to be around 20 to 25 months.
Lastly, we demonstrated superior efficacy of [Rybrevant] plus [Leclaza] in the first-line setting compared to a variable treatment in the first-line setting from the real-world data. So I assume that all these data suggests the potential of [Rybrevant] plus [Leclaza] in the first-line setting.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
